 Patent Application Title |
Patent App Num. |
Date |
| Method of reducing tissue loss in pancreatic islet cell transplantation | 20110008343 | 20110113 |
| Methods for reducing rejection of pancreatic islet cells transplanted into a subject are disclosed. The methods involve transplanting pancreatic islet cells into a subject in the presence of a complement inhibitor, alone or combined with dextran sulfate.
... |
| Injectable hydrogel microspheres from aqueous two-phase system | 20100316717 | 20101216 |
| Injectable hydrogel microspheres are prepared by forming an emulsion where hydrogel precursors are in a disperse aqueous phase and polymerizing the hydrogel precursors. In a preferred case, the hydrogel precursors are poly(ethylene glycol) diacrylate and N-isopropylacrylamide and the continuous phase of the emulsion is an aqueous solution of dextran and a dextran solubility reducer. The microspheres will load protein, e.g., cytokines, from aqueous solution.
... |
| Inhibiting agent for inhibition of angiogenesis, a method for preparing the agent, a method for modifying the agent and its use for manufacturing a medicament for treating tumor | 20100305303 | 20101202 |
| a highly efficient antiangiogenesis agent, which is a polypeptide for inhibition of angiogenesis Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro, connected with a polypeptide containing Arg-Gly-Asp on its one end or two ends is provided. The inhibiting agent can be synthesized or gene engineered. It also relates to a physiochemical method for modifying the antiangiogenesis agent. Polypeptides with weight percentage of 1-70% preferably about 20-50% are mixed with 20%-95% polyethylene glycol, or heparin, or dextran, or polyvinylpyrrolidone, or polyethylene glycol-poly-amino acid copolymer, or palmitic acid or poly-sialic acid or liposomes solutions; preferably about 50-93% of the above modified substances are fully mixed even and shaken at a shaker at 4° C.-40° C., preferably 25° C.-37° C. for more than 10 min, and the modified substances are separated through appropriate methods. Furthermore, it... |
| Surgical hydrogel | 20100291055 | 20101118 |
| The invention provides a hydrogel suitable for use in wound healing, particularly for reducing post-surgical adhesions. The hydrogel comprises cross-linked derivatives of chitosan and dextran polymers. The hydrogel forms when solutions of the polymers are combined.
... |
| Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans | 20100284972 | 20101111 |
| Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.
... |
Subscribe to updates on this page: Dextran RSS  |
| Recombinant production of heparin binding proteins | 20100261888 | 20101014 |
| A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate.
... |
| Biocompatible and biodegradable biopolymer matrix | 20100260845 | 20101014 |
| The present invention provides a biodegradable biopolymer matrix for surgical and/or therapeutic use comprising chitosan hydrochloride and dextran dialdehyde is in the ratio of 1:1 to 1:2. The invention further provides a process for preparing the biopolymer matrix and a kit for a surgical and/or therapeutic use comprising the biopolymer matrix.
... |
| Dextran-based polymer tissue adhesive for medical use | 20100255101 | 20101007 |
| A tissue adhesive formed by reacting an aminodextran containing primary amine groups with an oxidized dextran containing aldehyde groups is described. The dextran-based polymer tissue adhesive is particularly useful in medical applications where low swell and slow degradation are needed, for example sealing the dura, ophthalmic procedures, tissue repair, antiadhesive applications, drug delivery, and as a plug to seal a fistula or the punctum.
... |
| Ophthalmic composition | 20100249062 | 20100930 |
| The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a glucose.
... |
| Ophthalmic composition | 20100239518 | 20100923 |
| The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member (s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid.
... |
| System and method for regeneration of a fluid | 20100234795 | 20100916 |
| A method and a system for regenerating a body fluid, such as a peritoneal dialysis fluid. The body fluid is removed into an extracorporeal circuit comprising an electrofilter for removing charged ions from the body fluid, a nanofilter for removing large molecules, such as Dextran 40, and a reverse osmosis filter for concentrating the body fluid, for producing a synthetic urine to be discarded. The removed ions and large molecules are returned to the patient together with pure water from the reverse osmosis filter through an ultrafilter.
... |
| Ophthalmic composition | 20100216741 | 20100826 |
| The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) one or more member(s) selected from the group consisting of chondroitin sulfate, alginic acid and salts thereof; and (C) a nonionic surfactant.
... |
| Stabilized enzyme compositions | 20100215711 | 20100826 |
| A medical device includes a base material having an immobilized fibrinolytic enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kDa). The medical device is formed from at least a base material. A fibrinolytic enzyme is immobilized on the base material. The fibrinolytic enzyme is stabilized with a dextran sulfate having a molecular weight of less than 40 (kDa).
... |
Subscribe to updates on this page: Dextran RSS |
| kind of piperphentonamine hydrochloride lyophilized powder for injection and preparation and use thereof | 20100197731 | 20100805 |
| A kind of piperphentonamine hydrochloride lyophilized powder for injection and a preparation method thereof. The injection is prepared by one portion of piperphentonamine hydrochloride, 2.5-30 parts of excipient and 400-600 parts of water for injection with pH 1.5-5.5 via freeze-drying. The excipient is mannitol, dextran, lactose, saccharose, polyethylene glycol, poloxamer, glycine, etc.; It is preferred that the injection comprises one part of piperphentonamine hydrochloride, 10 parts of mannitol and 500 parts of water for injection with pH 2.0-3.0. The product is prepared by adding said piperphentonamine hydrochloride and excipient into water for injection, heating at 40° C.-90° C., ultrasonic dissolving, degerming, individually packing, pre-freezing and multistage drying, and packaging. Individually packing into a tubular glass bottle with brown color is preferred. The appearance, color & luster... |
| Room temperature stable agarose solutions | 20100196589 | 20100805 |
| Room temperature stable, non-gelling polysaccharide solutions such as agaroses, dextrans and cyclodextrans are made by the present invention. It has been found that by incorporating certain gel-inhibiting additives into an aqueous polysaccharide solution, the gel point is reduced or eliminated and the solution remains liquid at room temperature indefinitely. Additives that have been found to work include salts, such as lithium chloride and zinc chloride and bases, such as sodium hydroxide and lithium hydroxide. Mixtures of said salts and said bases can also be used with the same desired results. The composition of these solutions of the present idea can be further modified to include other additives, such as organic co-solvents or non-solvents, pH modifiers, surfactants or other polymers to customize the properties of the solution... |
| Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran | 20100196272 | 20100805 |
| The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce 99mTc-pertechnetate, Ascorbic Acid to reduce stannic ions to stannous ions to maintain a reducing environment, α,α-Trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and Glycine to transchelate Technetium-99m under highly acidic conditions to facilitate radiolabeling DTPA-dextran with high radiochemical purity. In addition, the invention pertains to methods for making and using the compositions. The reconstitution of the lyophilized composition by 99mTc-pertechnetate, resulting in radiolabeled 99mTc-DTPA-dextran in a composition between pH 3 to 4. This invention contains a Diluent vial, which when used will shift the pH to a moderately... |
| Compositions and methods for storage of bacterial suspensions | 20100190237 | 20100729 |
| A medium composition is provided. The medium composition comprising about: NaCl/KCl 1.0-3.0%; Inositol/lactose/trehalose/dextran 0.5-7.0%; Mg/Ca 0.0-300 mM; Yeast Extract/Casamino acids 0.01-0.05%; BSA/egg albumin 0.02-1.0%; and Ethanol/methanol/propanol 0.1-3.5%.
... |
| Sputum dissolving suctioning solution for endotracheal and tracheostomy tubes | 20100189808 | 20100729 |
| A composition for dissolving or reducing the viscosity of sputum on a surface of a device includes an effective amount of glycerol and an effective amount of dextran sulfate in a saline solution. The effective amount of glycerol is between about 30-50% and the effective amount of dextran sulfate is between about 10-30%. The composition may further include an antimicrobial agent.
... |
| Pharmaceutical compositions comprising dextran with a molecular weight of 1.0-100 kda and processes for their preparation | 20100172950 | 20100708 |
| A solid or semisolid implant obtainable by providing a liquid composition comprising an aqueous solution of dextran with molecular weight of 1.0-100 kDa and introducing the liquid composition into the body of a mammal, whereby the implant is formed in situ in the body of the mammal. A process for preparing a composition useful for biomedical application, comprising the steps of providing a liquid composition comprising an aqueous solution of dextran having a molecular weight of 1-100 kDa; and bringing the liquid composition to solidify; whereby water is gradually eliminated from the liquid composition during the solidification. A biomedical article prepared from the composition.
... |
| Oral insulin composition and methods of making and using thereof | 20100167985 | 20100701 |
| A method of lowering blood glucose in a mammal includes orally administering a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal. The composition may be a one phase or a structured multi-phase composition for controlled release of insulin.
... |
| Oral insulin composition and methods of making and using thereof | 20100166855 | 20100701 |
| A method of lowering blood glucose in a mammal includes orally administering a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal. The composition may be a one phase or a structured multi-phase composition for controlled release of insulin.
... |
| Method of preparing decellularized soft tissue, graft and culture material | 20100145444 | 20100610 |
| It is intended to provide a method of preparing a decellularized soft tissue whereby swelling after an ultrahigh pressure treatment can be inhibited, etc. The above-described method of preparing a decellularized soft tissue comprises the application step wherein an ultrahigh hydrostatic pressure is applied to an isolated soft tissue in a medium to thereby disrupt cells in the soft tissue, and the removal step wherein the disrupted cells are removed. As the medium, use is made of an aqueous solution containing a water-soluble polysaccharide such as dextran.
... |
| A use of hypertonic solution composition in manufacturing medicaments for promoting wound healing | 20100136140 | 20100603 |
| A use of a hypertonic solution composition in manufacturing medicaments used during the perioperative period for promoting wound healing, said composition consists of 1.5%-6.9% (w/v) of one or more substances selected from sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, calcium chloride and calcium gluconate, 3%-18% (w/v) of one or more of the substances selected from hydroxyethyl starch, dextran, carboxymethyl starch, polyvinyl pyrrolidone and gelatin derivatives, and the remainder of conventional injection, provided that the amount of sodium chloride in the composition is not less than 1.5% (w/v), and the concentration of sodium ion is not more than the one equivalent to the concentration of sodium ion in 6.9% (w/v) sodium chloride solution. The hypertonic solution composition can be administered as transfusion before operation, during operation,... |
| Method of treating graft-rejection using dextran sulfate | 20100113389 | 20100506 |
| The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible.
... |
| Synthesis of nanoassemblies containing luminescent quantum dots and magnetic nanoparticles | 20100112716 | 20100506 |
| Negatively charged luminescent CdSe—ZnS quantum dots (QDs) were successfully incorporated into novel luminescent glyconanospheres averaging around 190 nm in diameter through electrostatic interactions with carboxymethyldextran (CM-dextran) and polylysine. The glyconanospheres preferably contain as well carboxyl-modified iron oxide nanocrystals. In addition to electrostatic attraction between the negatively charged dextran, the negatively charged CdSe—ZnS QDs (and negatively charged iron oxide nanocrystals, if present), and the positively charged polylysine, covalent amide bonds were introduced to cross link the QDs (and negatively charged iron oxide nanocrystals, if present) with the polysaccharide matrix to further stabilize the glyconanospheres. The dextran residues on the surface of the nanospheres show high affinity toward the glucose binding protein-Concanavalin A (Con A). As a result, these luminescent CdSe—ZnS QD incorporated glyconanospheres are a useful tool... |
| Process for producing and purifying factor viii and its derivatives | 20100112641 | 20100506 |
| Disclosed is a method for producing proteins having factor VIII procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate. This invention also relates to a method of purifying target molecules from the culture medium containing both a target molecule and selected inhibitors by affinity chromatography.
... |
| Novel hydrogel compositions and methods of using | 20100112014 | 20100506 |
| Disclosed are novel agarose, methylcellulose, and dextran hydrogels. Further disclosed are methods of making and using the hydrogels.
... |
| Separation matrix for viral purification | 20100099163 | 20100422 |
| The present invention relates to a method of preparing a separation matrix comprising at least one insoluble carrier to which sulphate ligands have been attached via extenders, which method comprises coupling, in a first step, of the sulphate ligands to the extenders and, in a subsequent step, attaching the extenders to an insoluble carrier. The invention also relates to a separation matrix comprised of at least one insoluble carrier to which sulphate ligands have been attached via extenders. Advantageously, no sulphate ligands are directly attached to the insoluble carrier. The extenders may be natural polymers, such as dextran, and the insoluble carrier may be made from natural polymers, such as agarose, or synthetic polymers. The invention also relates to a method of purifying virus, such as... |
| Method of neuroprotection from oxidant injury using metal oxide nanoparticles | 20100098768 | 20100422 |
| A metal oxide nanoparticle composition including a cerium oxide nanoparticle and a metal adapted to enhance the neuroprotective activity of the cerium oxide nanoparticle. The metal can include noble metals such as platinum, and rare earth metals such as gadolinium, samarium, titanium, yttrium, zirconium, and a combination thereof Another metal oxide nanoparticle composition including a cerium oxide nanoparticle and a surface modifier, such as polyethylene oxide, polyethylene imine, dextran, polylactic acid, chitosan, alginate, and a combination thereof is provided. A method of using the metal oxide nanoparticle compositions as neuroprotective agents for the inactivation of reactive oxygen species in nervous tissues is also provided. More specifically, a neuroprotective method using the metal oxides such as ceria, yttria, or mixed ceria and yttria (or any of the... |
| Methods and compositions of inhibiting complement and cellular activation with dextran sulfate | 20100087393 | 20100408 |
| A method of inhibiting the adverse effects of complement pathway, activation products in a subject comprising administering to the subject an amount of Dextran Sulfate effective to inhibit formation of alternative complement pathway activation product.
... |
| Method of reducing tissue loss in pancreatic islet cell transplantation | 20110008343 | 20110113 |
| Methods for reducing rejection of pancreatic islet cells transplanted into a subject are disclosed. The methods involve transplanting pancreatic islet cells into a subject in the presence of a complement inhibitor, alone or combined with dextran sulfate.
... |
| Injectable hydrogel microspheres from aqueous two-phase system | 20100316717 | 20101216 |
| Injectable hydrogel microspheres are prepared by forming an emulsion where hydrogel precursors are in a disperse aqueous phase and polymerizing the hydrogel precursors. In a preferred case, the hydrogel precursors are poly(ethylene glycol) diacrylate and N-isopropylacrylamide and the continuous phase of the emulsion is an aqueous solution of dextran and a dextran solubility reducer. The microspheres will load protein, e.g., cytokines, from aqueous solution.
... |
| Inhibiting agent for inhibition of angiogenesis, a method for preparing the agent, a method for modifying the agent and its use for manufacturing a medicament for treating tumor | 20100305303 | 20101202 |
| a highly efficient antiangiogenesis agent, which is a polypeptide for inhibition of angiogenesis Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro, connected with a polypeptide containing Arg-Gly-Asp on its one end or two ends is provided. The inhibiting agent can be synthesized or gene engineered. It also relates to a physiochemical method for modifying the antiangiogenesis agent. Polypeptides with weight percentage of 1-70% preferably about 20-50% are mixed with 20%-95% polyethylene glycol, or heparin, or dextran, or polyvinylpyrrolidone, or polyethylene glycol-poly-amino acid copolymer, or palmitic acid or poly-sialic acid or liposomes solutions; preferably about 50-93% of the above modified substances are fully mixed even and shaken at a shaker at 4° C.-40° C., preferably 25° C.-37° C. for more than 10 min, and the modified substances are separated through appropriate methods. Furthermore, it... |
| Surgical hydrogel | 20100291055 | 20101118 |
| The invention provides a hydrogel suitable for use in wound healing, particularly for reducing post-surgical adhesions. The hydrogel comprises cross-linked derivatives of chitosan and dextran polymers. The hydrogel forms when solutions of the polymers are combined.
... |
| Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans | 20100284972 | 20101111 |
| Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.
... |
| Recombinant production of heparin binding proteins | 20100261888 | 20101014 |
| A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate.
... |
| Biocompatible and biodegradable biopolymer matrix | 20100260845 | 20101014 |
| The present invention provides a biodegradable biopolymer matrix for surgical and/or therapeutic use comprising chitosan hydrochloride and dextran dialdehyde is in the ratio of 1:1 to 1:2. The invention further provides a process for preparing the biopolymer matrix and a kit for a surgical and/or therapeutic use comprising the biopolymer matrix.
... |
| Dextran-based polymer tissue adhesive for medical use | 20100255101 | 20101007 |
| A tissue adhesive formed by reacting an aminodextran containing primary amine groups with an oxidized dextran containing aldehyde groups is described. The dextran-based polymer tissue adhesive is particularly useful in medical applications where low swell and slow degradation are needed, for example sealing the dura, ophthalmic procedures, tissue repair, antiadhesive applications, drug delivery, and as a plug to seal a fistula or the punctum.
... |
| Ophthalmic composition | 20100249062 | 20100930 |
| The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a glucose.
... |
| Ophthalmic composition | 20100239518 | 20100923 |
| The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member (s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid.
... |
| System and method for regeneration of a fluid | 20100234795 | 20100916 |
| A method and a system for regenerating a body fluid, such as a peritoneal dialysis fluid. The body fluid is removed into an extracorporeal circuit comprising an electrofilter for removing charged ions from the body fluid, a nanofilter for removing large molecules, such as Dextran 40, and a reverse osmosis filter for concentrating the body fluid, for producing a synthetic urine to be discarded. The removed ions and large molecules are returned to the patient together with pure water from the reverse osmosis filter through an ultrafilter.
... |
| Ophthalmic composition | 20100216741 | 20100826 |
| The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) one or more member(s) selected from the group consisting of chondroitin sulfate, alginic acid and salts thereof; and (C) a nonionic surfactant.
... |
| Stabilized enzyme compositions | 20100215711 | 20100826 |
| A medical device includes a base material having an immobilized fibrinolytic enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kDa). The medical device is formed from at least a base material. A fibrinolytic enzyme is immobilized on the base material. The fibrinolytic enzyme is stabilized with a dextran sulfate having a molecular weight of less than 40 (kDa).
... |
| kind of piperphentonamine hydrochloride lyophilized powder for injection and preparation and use thereof | 20100197731 | 20100805 |
| A kind of piperphentonamine hydrochloride lyophilized powder for injection and a preparation method thereof. The injection is prepared by one portion of piperphentonamine hydrochloride, 2.5-30 parts of excipient and 400-600 parts of water for injection with pH 1.5-5.5 via freeze-drying. The excipient is mannitol, dextran, lactose, saccharose, polyethylene glycol, poloxamer, glycine, etc.; It is preferred that the injection comprises one part of piperphentonamine hydrochloride, 10 parts of mannitol and 500 parts of water for injection with pH 2.0-3.0. The product is prepared by adding said piperphentonamine hydrochloride and excipient into water for injection, heating at 40° C.-90° C., ultrasonic dissolving, degerming, individually packing, pre-freezing and multistage drying, and packaging. Individually packing into a tubular glass bottle with brown color is preferred. The appearance, color & luster... |
| Room temperature stable agarose solutions | 20100196589 | 20100805 |
| Room temperature stable, non-gelling polysaccharide solutions such as agaroses, dextrans and cyclodextrans are made by the present invention. It has been found that by incorporating certain gel-inhibiting additives into an aqueous polysaccharide solution, the gel point is reduced or eliminated and the solution remains liquid at room temperature indefinitely. Additives that have been found to work include salts, such as lithium chloride and zinc chloride and bases, such as sodium hydroxide and lithium hydroxide. Mixtures of said salts and said bases can also be used with the same desired results. The composition of these solutions of the present idea can be further modified to include other additives, such as organic co-solvents or non-solvents, pH modifiers, surfactants or other polymers to customize the properties of the solution... |
| Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran | 20100196272 | 20100805 |
| The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce 99mTc-pertechnetate, Ascorbic Acid to reduce stannic ions to stannous ions to maintain a reducing environment, α,α-Trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and Glycine to transchelate Technetium-99m under highly acidic conditions to facilitate radiolabeling DTPA-dextran with high radiochemical purity. In addition, the invention pertains to methods for making and using the compositions. The reconstitution of the lyophilized composition by 99mTc-pertechnetate, resulting in radiolabeled 99mTc-DTPA-dextran in a composition between pH 3 to 4. This invention contains a Diluent vial, which when used will shift the pH to a moderately... |
| Compositions and methods for storage of bacterial suspensions | 20100190237 | 20100729 |
| A medium composition is provided. The medium composition comprising about: NaCl/KCl 1.0-3.0%; Inositol/lactose/trehalose/dextran 0.5-7.0%; Mg/Ca 0.0-300 mM; Yeast Extract/Casamino acids 0.01-0.05%; BSA/egg albumin 0.02-1.0%; and Ethanol/methanol/propanol 0.1-3.5%.
... |
| Sputum dissolving suctioning solution for endotracheal and tracheostomy tubes | 20100189808 | 20100729 |
| A composition for dissolving or reducing the viscosity of sputum on a surface of a device includes an effective amount of glycerol and an effective amount of dextran sulfate in a saline solution. The effective amount of glycerol is between about 30-50% and the effective amount of dextran sulfate is between about 10-30%. The composition may further include an antimicrobial agent.
... |
| Pharmaceutical compositions comprising dextran with a molecular weight of 1.0-100 kda and processes for their preparation | 20100172950 | 20100708 |
| A solid or semisolid implant obtainable by providing a liquid composition comprising an aqueous solution of dextran with molecular weight of 1.0-100 kDa and introducing the liquid composition into the body of a mammal, whereby the implant is formed in situ in the body of the mammal. A process for preparing a composition useful for biomedical application, comprising the steps of providing a liquid composition comprising an aqueous solution of dextran having a molecular weight of 1-100 kDa; and bringing the liquid composition to solidify; whereby water is gradually eliminated from the liquid composition during the solidification. A biomedical article prepared from the composition.
... |
| Oral insulin composition and methods of making and using thereof | 20100167985 | 20100701 |
| A method of lowering blood glucose in a mammal includes orally administering a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal. The composition may be a one phase or a structured multi-phase composition for controlled release of insulin.
... |
| Oral insulin composition and methods of making and using thereof | 20100166855 | 20100701 |
| A method of lowering blood glucose in a mammal includes orally administering a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal. The composition may be a one phase or a structured multi-phase composition for controlled release of insulin.
... |
| Method of preparing decellularized soft tissue, graft and culture material | 20100145444 | 20100610 |
| It is intended to provide a method of preparing a decellularized soft tissue whereby swelling after an ultrahigh pressure treatment can be inhibited, etc. The above-described method of preparing a decellularized soft tissue comprises the application step wherein an ultrahigh hydrostatic pressure is applied to an isolated soft tissue in a medium to thereby disrupt cells in the soft tissue, and the removal step wherein the disrupted cells are removed. As the medium, use is made of an aqueous solution containing a water-soluble polysaccharide such as dextran.
... |
| A use of hypertonic solution composition in manufacturing medicaments for promoting wound healing | 20100136140 | 20100603 |
| A use of a hypertonic solution composition in manufacturing medicaments used during the perioperative period for promoting wound healing, said composition consists of 1.5%-6.9% (w/v) of one or more substances selected from sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, calcium chloride and calcium gluconate, 3%-18% (w/v) of one or more of the substances selected from hydroxyethyl starch, dextran, carboxymethyl starch, polyvinyl pyrrolidone and gelatin derivatives, and the remainder of conventional injection, provided that the amount of sodium chloride in the composition is not less than 1.5% (w/v), and the concentration of sodium ion is not more than the one equivalent to the concentration of sodium ion in 6.9% (w/v) sodium chloride solution. The hypertonic solution composition can be administered as transfusion before operation, during operation,... |
| Method of treating graft-rejection using dextran sulfate | 20100113389 | 20100506 |
| The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible.
... |
| Synthesis of nanoassemblies containing luminescent quantum dots and magnetic nanoparticles | 20100112716 | 20100506 |
| Negatively charged luminescent CdSe—ZnS quantum dots (QDs) were successfully incorporated into novel luminescent glyconanospheres averaging around 190 nm in diameter through electrostatic interactions with carboxymethyldextran (CM-dextran) and polylysine. The glyconanospheres preferably contain as well carboxyl-modified iron oxide nanocrystals. In addition to electrostatic attraction between the negatively charged dextran, the negatively charged CdSe—ZnS QDs (and negatively charged iron oxide nanocrystals, if present), and the positively charged polylysine, covalent amide bonds were introduced to cross link the QDs (and negatively charged iron oxide nanocrystals, if present) with the polysaccharide matrix to further stabilize the glyconanospheres. The dextran residues on the surface of the nanospheres show high affinity toward the glucose binding protein-Concanavalin A (Con A). As a result, these luminescent CdSe—ZnS QD incorporated glyconanospheres are a useful tool... |
| Process for producing and purifying factor viii and its derivatives | 20100112641 | 20100506 |
| Disclosed is a method for producing proteins having factor VIII procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate. This invention also relates to a method of purifying target molecules from the culture medium containing both a target molecule and selected inhibitors by affinity chromatography.
... |
| Novel hydrogel compositions and methods of using | 20100112014 | 20100506 |
| Disclosed are novel agarose, methylcellulose, and dextran hydrogels. Further disclosed are methods of making and using the hydrogels.
... |
| Separation matrix for viral purification | 20100099163 | 20100422 |
| The present invention relates to a method of preparing a separation matrix comprising at least one insoluble carrier to which sulphate ligands have been attached via extenders, which method comprises coupling, in a first step, of the sulphate ligands to the extenders and, in a subsequent step, attaching the extenders to an insoluble carrier. The invention also relates to a separation matrix comprised of at least one insoluble carrier to which sulphate ligands have been attached via extenders. Advantageously, no sulphate ligands are directly attached to the insoluble carrier. The extenders may be natural polymers, such as dextran, and the insoluble carrier may be made from natural polymers, such as agarose, or synthetic polymers. The invention also relates to a method of purifying virus, such as... |
| Method of neuroprotection from oxidant injury using metal oxide nanoparticles | 20100098768 | 20100422 |
| A metal oxide nanoparticle composition including a cerium oxide nanoparticle and a metal adapted to enhance the neuroprotective activity of the cerium oxide nanoparticle. The metal can include noble metals such as platinum, and rare earth metals such as gadolinium, samarium, titanium, yttrium, zirconium, and a combination thereof Another metal oxide nanoparticle composition including a cerium oxide nanoparticle and a surface modifier, such as polyethylene oxide, polyethylene imine, dextran, polylactic acid, chitosan, alginate, and a combination thereof is provided. A method of using the metal oxide nanoparticle compositions as neuroprotective agents for the inactivation of reactive oxygen species in nervous tissues is also provided. More specifically, a neuroprotective method using the metal oxides such as ceria, yttria, or mixed ceria and yttria (or any of the... |
| Methods and compositions of inhibiting complement and cellular activation with dextran sulfate | 20100087393 | 20100408 |
| A method of inhibiting the adverse effects of complement pathway, activation products in a subject comprising administering to the subject an amount of Dextran Sulfate effective to inhibit formation of alternative complement pathway activation product.
... |
| Compositions for use as a signal generation component and methods of using same | 20090325316 | 20091231 |
| wherein R is one or more substituents, each substituent comprising an electron donating group; n=2-10; x=1-2; and y=2-4.
... |
| Superparamagnetic nanoparticles based on iron oxides with modified surface, method of their preparation and application | 20090309597 | 20091217 |
| The preparation of labelled cells proceeds by adding to the complete culture medium 5-20 μl, to advantage 10 μl, of a colloid containing 0.05-45 mg iron oxide per ml, to advantage 1-5 mg iron oxide per ml of the medium, and culturing the cells for a period of 1-7 days, to advantage for 1-3 days, at 37° C. and 5% of CO2.
... |
| Antiviral composition | 20090286757 | 20091119 |
| Chemical compounds, being the alkyl sulfate of sulfated saccharides, particularly, dextrin, dextran, and cyclodextrin, and pharmaceutical compositions containing these compounds. The compounds of the invention provide antiviral activity, particularly in the treatment and prevention of sexually-transmitted diseases. Methods of treating viral infection and preventing viral transmission include administration include administration of the compounds of the invention orally, topically, subcutaneously, by muscular injection, by intraperitoneal injection and by intravenous injection.
... |
| Pharmaceutical compositions comprising dextran with a molecular weight of 1.0-100 kda and processes for their preparation | 20090281020 | 20091112 |
| A solid or semisolid implant obtainable by providing a liquid composition comprising an aqueous solution of dextran with molecular weight of 1.0-100 kDa and introducing the liquid composition into the body of a mammal, whereby the implant is formed in situ in the body of the mammal. A process for preparing a composition useful for biomedical application, comprising the steps of providing a liquid composition comprising an aqueous solution of dextran having a molecular weight of 1-100 kDa; and bringing the liquid composition to solidify; whereby water is gradually eliminated from the liquid composition during the solidification. A biomedical article prepared from the composition.
... |
| Serum-free mammalian cell culture medium, and uses thereof | 20090280533 | 20091112 |
| The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.
... |
| Serum-free mammalian cell culture medium, and uses thereof | 20090280532 | 20091112 |
| The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.
... |
| Pharmaceutical compositions comprising dextran with a molecular weight of 1.0-100 kda and processes for their preparation | 20090281020 | 20091112 |
| A solid or semisolid implant obtainable by providing a liquid composition comprising an aqueous solution of dextran with molecular weight of 1.0-100 kDa and introducing the liquid composition into the body of a mammal, whereby the implant is formed in situ in the body of the mammal. A process for preparing a composition useful for biomedical application, comprising the steps of providing a liquid composition comprising an aqueous solution of dextran having a molecular weight of 1-100 kDa; and bringing the liquid composition to solidify; whereby water is gradually eliminated from the liquid composition during the solidification. A biomedical article prepared from the composition.
... |
| Serum-free mammalian cell culture medium, and uses thereof | 20090280533 | 20091112 |
| The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.
... |
| Serum-free mammalian cell culture medium, and uses thereof | 20090280532 | 20091112 |
| The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.
... |
| Construction of new variants of dextransucrase dsr-s by genetic engineering | 20090258389 | 20091015 |
| The present invention relates to a recombinant process for the production of truncated and/or mutated dextransucrases while conserving their enzymatic activity and/or their specificity in the synthesis of the α-1,6 bonds. More precisely, the present invention relates to nucleic acid sequences of truncated and/or mutated dextransucrases, vectors containing said nucleic acid sequences and host cells transformed by sequences encoding truncated and/or mutated dextransucrases. In a further aspect, the invention concerns a method for producing, in a recombinant manner, truncated and/or mutated dextransucrases which conserve their enzymatic activity and/or which conserve their specificity in the synthsis of α-1,6 bonds and however can produce, from saccharose, dextrans with high molar mass and with modified rheological properties, compared with the properties of dextran obtained with the native enzyme in... |
| Dry hemostatic compositions and methods for their preparation | 20090227779 | 20090910 |
| Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.
... |
| Formulations limiting spread of pulmonary infections | 20090208581 | 20090820 |
| Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles. These may include proteins such as albumin or... |
| Formulations limiting spread of pulmonary infections | 20090208581 | 20090820 |
| Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles. These may include proteins such as albumin or... |
| Nucleic acid molecules coding for a dextransaccharase catalysing the synthesis of dextran with alpha 1,2 osidic sidechains | 20090123448 | 20090514 |
| The invention relates to an isolated polypeptide with an glycosyl transferase enzymatic activity for producing dextrans with .alpha.(1.fwdarw.2) sidechains, comprising at least one region for bonding to glucan and a catalytically active region situated beyond the region bonding to glucan. The invention further relates to polynucleotides coding for said enzymes and vectors containing the same.
... |
| Methods and compositions for regenerating connective tissue | 20090123547 | 20090514 |
| Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament.
... |
| Methods and compositions for regenerating connective tissue | 20090124552 | 20090514 |
| Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament.
... |
| Collagenous tissue compositions | 20090124708 | 20090514 |
| Implant compositions are disclosed consisting of a biocompatible carrier medium such as a saline or dextran solution and particles of collagenous material dispersed therein. The collagenous material is derived from tissue which has been milled to provide fragments of collagen fibres which preserve the architecture of the original fibres and their molecular structure. The collagenous material is also substantially free of non-fibrous tissue proteins, glycoproteins, cellular elements and lipids or lipid residues, and is non-cytotoxic. By suitable choice of particle size and concentration, the composition may be presented in injectable form or as a paste. The compositions are suitable for application in cosmetic and reconstruction surgery.
... |
| Preparation for transferring nucleic acid into cell | 20090117657 | 20090507 |
| The present invention provides a composition comprising a polysaccharide to enhance transfection of a cell with a nucleic acid. The present invention also provides a method for transfecting a cell with a nucleic acid comprising the steps of forming a polyionic complex of the nucleic acid and a polysaccharide; and bringing about uptake of the polyionic complex by the cell. Preferably, the cell is selected from bone marrow mesenchymal stem cells, nervous system cell lines, adipose tissue stem cells, immunocytes, neurons, and chondrocytes. Moreover, preferably the polysaccharide is a cationized pullulan derivative, a cationized dextran derivative, or a cationized mannan derivative.
... |
| Phenobarbital derivatives useful in immunoassay | 20090104713 | 20090423 |
| Phenobarbital derivatives synthesized out of the alkyl chain at the 5-position, particularly with hydrophilic properties, and carrying an active ester at the end, allow formation of aminodextran conjugates that give curves in the desired range of the assay in the ONLINE TDM microparticle assay format when matched against the Roche FPIA antibody specific for phenobarbital (“an antibody specific for phenobarbital”).
... |
| Magnetic beads | 20090092837 | 20090409 |
| The present invention relates to magnetic beads in the form of composite beads with an inner core of metal particles, which are coated with an inert synthetic polymer and thereafter a hydrophilic porous polymer, preferably dextran. This provides porous biocompatible beads without metal leakage. This construction also allows for simple and convenient handling of cell expansion media by magnetism.
... |
| Bioactive molecular matrix and methods of use in the treatment of disease | 20090081156 | 20090326 |
| The composition may comprise one or more types of biomodulatory molecules selected from the group consisting of cytokines, bacterial molecules, receptor ligands, antigen binding fragments of antibodies, heat shock proteins, and integrins. The composition may further comprise one or more disease-specific antigens to stimulate an immune response. The disease-specific antigens may be selected from the group consisting of tumor-associated antigens, infectious disease-associated antigens, autoimmune-associated antigens, parasitic antigens, bacterial antigens, and viral antigens. In addition the composition may further comprise a solid support to which the cross-linked biomodulatory molecules are affixed. The solid support may be selected from the group consisting of Dextran, chitosan, alginate, poly-DL lactide polyglycolide, polyglycolide, or alum.
... |
| Bi-functional polymer-attached inhibitors of influenza virus | 20090081249 | 20090326 |
| Antimicrobial compositions containing two or more antiviral agents coupled to a polymer and methods of making and using the compositions, are described herein. In one embodiment, two or more antiviral agents are covalently coupled to the polymer. Suitable antiviral agents include, but are not limited to, sialic acid, zanamivir, oseltamivir, amantadine, rimantadine, and combinations thereof. The polymer is preferably a water-soluble, biocompatible polymer. Suitable polymers include, but are not limited to, poly(isobutylene-alt-maleic anhydride) (PIBMA), poly(aspartic acid), poly(l-glutamic acid), polylysine, poly(acrylic acid), plyaginic acid, chitosan, carboxymethyl cellulose, carboxymethyl dextran, polyethyleneimine, and blends and copolymers thereof. In another embodiment, the compositions contain a physical mixture of polymer containing one antiviral agent and polymer containing a second antiviral agent. The compositions can be formulated for enteral or parenteral administration.... |
| Transformed plant expressing a dextransucrase and synthesizing a modified starch | 20090064372 | 20090305 |
| The present invention relates to plant cells and plants, which are genetically modified, wherein the genetic modification leads to the expression in plastids of such plant cells and plants of an enzyme having the activity of a dextransucrase. Furthermore, the present invention relates to means and methods for the manufacture of such plant cells and plants. Plant cells and plants of this type synthesis a modified starch. The present invention therefore also relates to the starch synthesized by the plant cells and plants according to the invention as well as to methods for the manufacture of the starch and to the manufacture of starch derivatives of this modified starch.
... |
| Device to reduce brain edema by surface dialysis and cooling | 20090048582 | 20090219 |
| We have developed a novel method of brain surface dialysis that reduces intracranial pressure and modifies movement of extracellular fluid in a rat model of brain injury. A chamber with a semipermeable membrane at the site of brain contact is perfused with a hyperosmolar solution (e.g. 15% dextran, inulin, hydroxyethyl starch). It is also capable of providing local brain cooling. In principle, osmotic forces draw water and small molecules from the injured brain into the dialysis chamber thereby reducing brain swelling. The dialysate does not move into the brain.
... |
| Sperm-blocking agent composition with contraceptive effect | 20090041743 | 20090212 |
| A sperm-blocking agent is disclosed. The composition comprises an aqueous solvent a gum which is a polysaccharide having about 0.3 to 10 wt % of the composition, wherein the polysaccharide is selected from the group consisting of celluloses and their derivatives, hemi-cellulose, fiber, starches and their derivatives, polydextrans and their derivatives, pectins and their derivatives, seaweed polysaccharids, their salts and derivatives and natural gums; and a lubricant being alcohols having about 0.5 to wt % of the composition, wherein the alcohol is at least one selected from polyethene glycol having a molecular weight of over 200, polypropylene glycol having a molecular weight poly(ethylene oxide) polymers and glycerin; wherein the viscosity of the composition is above 9000 cst.
... |
| Stabilized glycosaminoglycan preparations and related methods | 20090042834 | 20090212 |
| Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.)
... |
| Administration of copper to an animal | 20090029942 | 20090129 |
| The present invention is directed to the administration of copper to an animal using a composition containing copper dextran. A method is described for increasing the copper levels in an animal by the administration of a composition containing copper dextran. A preferred method of administration is intra muscularly. The use of this composition has been found to both address copper deficiencies in an animal, particularly deer.
... |
| Composition for promoting the proliferation of lactobacillus casei subsp. casei | 20080305090 | 20081211 |
| A composition for promoting bacterial proliferation and selectively proliferating Lactobacillus casei subsp. casei is disclosed, which includes a dextran. A variety of biological activities originating from L. casei subsp. casei can be sustained in a living body by selectively growing-proliferating and colonizing L. casei subsp. casei in the intestine of a human being, animal, or the like or by selectively growing-proliferating L. casei subsp. casei in the intestine, without supplying L. casei subsp. casei at all times.
... |
| Pharmaceutical compositions comprising dextran with a molecular weight of 1.0-100 kda and processes for their preparation | 20080305139 | 20081211 |
| A solid or semisolid implant obtainable by providing a liquid composition comprising an aqueous solution of dextran with molecular weight of 1.0-100 kDa and introducing the liquid composition into the body of a mammal, whereby the implant is formed in situ in the body of the mammal. A process for preparing a composition useful for biomedical application, comprising the steps of providing a liquid composition comprising an aqueous solution of dextran having a molecular weight of 1-100 kDa; and bringing the liquid composition to solidify; whereby water is gradually eliminated from the liquid composition during the solidification. A biomedical article prepared from the composition.
... |
| Emulsifiers and emulsions | 20080299281 | 20081204 |
| An emulsifier which is a protein/polysaccharide conjugate derived from whey protein and a non-ionic polysaccharide, more particularly dextran, maltodextrin or gum Arabic, is described together with its application in emulsions and beverages.
... |
| Dry hemostatic compositions and methods for their preparation | 20080286376 | 20081120 |
| Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.
... |
| Dermal filler composition | 20080279806 | 20081113 |
| Disclosed herein is a dermal filler composition. The composition includes polymethylmethacrylate (PMMA), cross-linked dextran, hydroxypropyl methylcellulose (HPMC), and physiological saline or distilled water. The composition rapidly restores volume at application sites by injection, does not require pre-testing, such as allergic skin testing, because it does not cause severe allergic reactions, is cheap, and is not easily degraded or absorbed in the body, thus ensuring a long-lasting volume augmentation effect. Due to the characteristics described above, the composition facilitates volume correction requiring a large amount (20 cc or greater) of dermal filler such as in augmentation phalloplasty.
... |
| Preparation comprising iron(iii) complex compounds and redox-active substance(s) | 20080269167 | 20081030 |
| A preparation is disclosed that comprises one or more iron(III) complex compounds which have a redox potential at pH 7 of from −324 mV to −750 mV relative to a normal hydrogen electrode (NHE), and one or more redox-active substances, wherein the carbohydrates are selected from the group consisting of dextrans and hydrogenated dextrans, dextrins, oxidised or hydrogenated dextrins, as well as pullulan, oligomers thereof and/or hydrogenated pullulans, and wherein the redox-active substance(s) is/are selected from the group consisting of ascorbic acid; vitamin E; cysteine; physiologically acceptable phenols/polyphenols selected from the group consisting of quercetin, rutin, flavones, flavonoids, hydroquinones; and glutathione, and in particular is ascorbic acid.
... |
| Assessment of biological activity of hepatocyte growth factor (hgf) | 20080261233 | 20081023 |
| In the present invention the methods for recognition of biologically active hepatocyte growth factor efficient for using in therapeutic components are presented. The biological activity can be determined using: i) an in vitro model of restitution of damaged cells, and/or ii) affinity measurements or epitope mapping using SPR, with the C-met receptor, anti-HGF antibodies or polysaccharides such as dextran, and/or iii) an animal model of hair growth rates. By these methods the activity of HGF in body secretions can be evaluated as well.
... |
| Method of preventing precipitation of a reactive substance-bound microparticle, and reagent containing the micro particle | 20080261328 | 20081023 |
| According to the present invention, precipitation of a reactive substance-bound microparticle can be prevented in a dispersion liquid, to make a concentration of the reactive substance-bound microparticle uniform in the dispersion liquid. The present invention provides a method of preventing precipitation of a reactive substance-bound microparticle. The method includes coexisting at least one selected from the group consisting of polyanion or its salt, dextran, cyclodextrin, polyethylene glycol, and glycerol, with the microparticle in a dispersion liquid.
... |
| Dextran functionalized by hydrophobic amino acids | 20080234227 | 20080925 |
| The invention relates to a dextran functionalized by at least one hydrophobic alpha-amino acid radical, said alpha-amino acid being grafted or bonded to the dextran by a bonding arm and a functional group. A hydrophobic amino acid radical is understood as being the product of coupling between the amine of the amino acid and an acid carried by the bonding arm, said dextran being amphiphilic at neutral pH. In an embodiment, the hydrophobic amino acid is selected from tryptophan derivatives, such as tryptophan, tryptophanol, tryptophanamide, 2-indole ethyl-amine and their alkaline cation salts. The present invention relates also to a pharmaceutical composition comprising one of the dextrans according to the invention.
... |
| Modified hydroxypolymer conjugates with killing effect on tumor cells | 20080221066 | 20080911 |
| The present invention is related to a modified hydroxypolymer conjugates preferably a guanidine-dextran conjugate having a tumor cell killing activity. The modified hydroxypolymer conjugate is used as medicine, particularly for manufacturing a medicine or tumor killing composition for treating tumors. A method for producing said hydroxypolymer conjugate and a method for killing cancer cells and treating tumors is also disclosed. The invention is also related to a method for killing tumor cells and treating tumors by administering an effective amount of the modified hydroxypolymer conjugate.
... |
| Nanoparticles for imaging atherosclerotic plaque | 20080206150 | 20080828 |
| Atherosclerosis is an inflammatory disease of the arterial walls and represents a significant health problem in developed nations. Described is a targeted Magnetic Resonance Imaging (MRI) contrast agent for in vivo imaging of early stage atherosclerosis. Early plaque development is characterized by the influx of macrophages, which express a class of surface receptors known collectively as the scavenger receptors (SR). The macrophage scavenger receptor class A (SRA) is highly expressed during early atherosclerosis. The macrophage SRA therefore presents itself as an ideal target for labeling of lesion formation. By coupling a known ligand for the scavenger receptor, dextran sulfate, to a MRI contrast agent, early plaque formation can be detected in vivo. Targeted MR contrast agents offer a unique opportunity to visualize early plaque development in... |
| Therapeutic delivery system comprising a high molecular weight peg-like compound | 20080206188 | 20080828 |
| The present invention provides a system for delivering a wide range of chemical and biological therapeutics, including protein therapeutics, via transepithelial routes. The system comprises a high molecular weight polyethylene glycol-like (HMW PEG-like) compound for use with a therapeutic compound. Optionally, the system comprises a composition containing one or more HMW PEGlike compounds and one or more therapeutics, supplemented with a protective polymer such as dextran and/or essential pathogen nutrients such as L-glutamine. Administered alone, the HMW PEG-like compounds also provide therapeutic benefits. Also provided are methods for preventing or treating epithelial diseases, disorders, or conditions, such as an epithelium at risk of developing gut-derived sepsis attributable to an intestinal pathogen, as well as methods for monitoring the administration of HMW PEG-like compounds.
... |
| Bone graft | 20080145392 | 20080619 |
| An improved demineralized bone matrix (DBM) or other matrix composition is provided that has been mixed with a stabilizing agent that acts as (1) a diffusion barrier, (2) a enzyme inhibitor, (3) a competitive substrate, or (4) a masking moiety. A diffusion barrier acts as a barrier so as to protect the osteoinductive factors found in DBM from being degraded by proteolytic and glycolytic enzymes at the implantation site. Stabilizing agents may be any biodegradable material such as starches, modified starches, cellulose, dextran, polymers, proteins, and collagen. As the stabilizing agents degrades or dissolves in vivo, the osteoinductive factors such as TGF-.beta., BMP, and IGF are activated or exposed, and the activated factors work to recruit cells from the preivascular space to the site of injury... |
| Methods and compositions for regenerating connective tissue | 20080145404 | 20080619 |
| Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament.
... |
| Cartilage repair mixture containing allograft chondrocytes | 20080133008 | 20080605 |
| The invention is directed toward a sterile cartilage defect implant material comprising milled lyophilized allograft cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or mixed polymers with allograft chondrocytes added in an amount ranging from 2.5×105 to 2.5×107.
... |
| Growth factor composition | 20080118542 | 20080522 |
| Also provided are a method of preparation in vitro of a bone graft substitute using the composition, a kit for carrying out the method, as well as use of the composition in the preparation of a medical device for generation of hard tissue in a mammalian subject in need thereof, and a method of generation of hard tissue at a desired site in a mammalian subject in need thereof.
... |
| Multiple point detacher system | 20080109057 | 20080508 |
| Embodiments of the invention include a method for treating an aneurysm, comprising: providing a biocompatible polymeric sleeve, string or coil or combination of sleeve, string or coil, made from a material selected from one or more of a group consisting of an acrylamide, a methacrylate, cyclodextran, synthetic elastin polymer, poly chelating amphiphilic polymers, hydrogels, hyaluronic acid conjugates, polyanhydrides, glycolipids, polysaccharides, and halamines, natural hydrogel, a synthetic hydrogel, silicone, polyurethane, polysulfone, cellulose, polyethylene, polypropylene, polyamide, polyimide, polyester, polytetrafluoroethylene, polyvinyl chloride, epoxy, phenolic, neoprene, polyisoprene, and a combination thereof; transporting the sleeve, string or coil to an aneurysm; filling the aneurysm with the sleeve, coil, or string; and detaching the sleeve, string or coil
... |
| Trace elements | 20080102074 | 20080501 |
| The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronisation preparation. The synchronisation preparation is a combination of injectable hormonal preparations, inplantable hormonal preparations, intravaginal hormonal preparation and other slow release hormonal preparation. The antibiotics include oral, injectable and implantable theurapeutic remedies. The vaccine includes antigens and a combination of antigens and adjuvents. The growth stimulants include zeranol, estradiol, testosterone, progesterone and trenbolone acetate. The dewormer includes macrocydic lactones, leramizoles, benzimidazoles and salicylanilides. The macrocydic lactones include doramectin, ivermectin, abamectin and moxidectin.
... |
| Dry hemostatic compositions and methods for their preparation | 20080085316 | 20080410 |
| Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.
... |
| Compositions and methods for inhibiting adhesions | 20080069857 | 20080320 |
| The present invention provides compositions and methods for inhibiting adhesions. The methods involve administering solutions containing hydrogel precursors such as polysaccharide derivatives, e.g., derivatives of hyaluronic acid, cellulose, or dextran, to a subject at a site where adhesions may form, e.g., as a consequence of surgery, injury, or infection. The hydrogel precursors, e.g., polysaccharide derivatives, become crosslinked following their administration to form a hydrogel that maintains tissue separation. In certain embodiments of the invention one or both solutions contains particles, e.g., polymeric nanoparticles or microparticles, so that a composite hydrogel containing the particles is formed. The solution(s), particle(s), or both, may contain a biologically active agent such as an agent that contributes to inhibiting adhesions. The biologically active agent may be covalently attached to a hydrogel... |
| Bioresorbable polymer matrices and methods of making and using the same | 20080069894 | 20080320 |
| A bioerodible composition for delivery of a bioactive agent is the reaction product of a reaction mixture which includes an oxidized dextran solution, and a mixture of solids containing a dihydrazide, a bioactive agent, and optionally a pH adjusting agent in an amount sufficient to achieve a pH of the reaction mixture of 6 or less. The composition may include a release agent for the controlled release of the bioactive agent from the composition. A bioactive agent may therefore be administered to a body site in need of the same by providing a first aliquot portion of a reaction mixture comprising an oxidized dextran solution, and a second aliquot portion of a reaction mixture comprising a mixture of solids comprised of a dihydrazide, a bioactive agent,... |
| Microfluidic system and coating method therefor | 20080056947 | 20080306 |
| A microfluidic system having a microchannel for the capillary transport of a liquid, in particular a body fluid for analytical purposes. The microchannel is provided with a surface coating comprising at least one hydrophilic substance selected from the group consisting of polyacrylic acid, polyacrylate, dextran sulfate and chondroitin sulfate. The invention also concerns a coating method that is suitable for this.
... |
| Evaluation and preservation solution | 20080057488 | 20080306 |
| An evaluation and preservation solution for human and animal organs, tissues and parts thereof is described, wherein it comprises serum albumin at a concentration of 55-105 g/L, a scavenger and coating compound, preferably dextran compounds and derivatives thereof having essentially the same structure at a concentration of 1-55 g/L weight, and a physiological serum concentration of salts and nutrients in a physiologically acceptable medium.
... |
| Recombinant production of heparin binding proteins | 20080032343 | 20080207 |
| A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate.
... |
| Core-shell particles | 20080032421 | 20080207 |
| Colloidal metal particles having a coating comprising non cross-linked, SH-activated dextran or aminodextran. Biomolecules may be linked directly or indirectly to the particles, which are useful as detection reagents in immunological assays.
... |
| Blood sugar detecting system | 20080020471 | 20080124 |
| A blood sugar detecting system using emission quantum dots is provided. A non-cyclodextran carbohydrate-containing molecule and a glucose-recognizing molecule respectively bind to an emission quantum dot and a light-absorbing molecule to form the blood sugar measuring system. When the non-cyclodextran carbohydrate-containing molecule and the glucose-recognizing molecule bind together to bring the emission quantum dot very close to the light-absorbing molecule, a fluorescence resonance energy transfer effect is happened between them. Glucose can compete with the non-cyclodextran carbohydrate-containing molecule for the binding site of the glucose-recognizing molecule to detect glucose concentration variation.
... |
| Bifunctionalized polysaccharides | 20080014250 | 20080117 |
| The present invention relates to a dextran and/or dextran derivative bifunctionalized by at least one imidazolyl radical Im and at least one hydrophobic group Hy, the said radical and the said group being each identical and/or different and grafted or bonded to the dextran and/or dextran derivative via one or more connecting arms R, Ri or Rh and functional groups F, Fi or Fh and the pharmaceutical compositions comprising one of the said dextrans and at least one active principle.
... |
| Viscous agent for ophthalmic use | 20070270378 | 20071122 |
| An object of the present invention is to provide an eyedrop which has a relatively low viscosity before instillation but is thickened on the eyeball surface at instillation. The eyedrop containing a viscous agent for ophthalmic use, which comprises a combination of hydroxyethylcellulose and dextran, exhibits a specific and synergistic thickening effect in the coexistence of mucin. Therefore, the eyedrop of the present invention is thickened on the eyeball surface upon contact with mucin in the precorneal tear film at instillation, whereby a desired pharmacological efficacy or refreshing feel can be sustained.
... |
| Method of modifying blood contact material and blood contact material inhibited from activating granulocyte | 20070270523 | 20071122 |
| An object of the present invention is to provide a method of modifying a blood contact material capable of reducing granulocyte activating action of the blood contact material in medical equipment used for parts which get contact with the blood. The present invention provides a method of modifying blood contact material characterized by granulocyte activating action when in contact with blood,the modifying blood contact material is considerably reduced compared with an original blood contact material by immobilizing a tryptophan derivative and a polyanionic compound to the blood contact material. Examples of the tryptophan derivative include tryptophan. Further, examples of the polyanionic compound include dextran sulfate.
... |
| Resin composition, molded product from resin composition and method for preparing resin composition | 20070270527 | 20071122 |
| Disclosed is a biodegradable resin composition containing at least one biodegradable organic high molecular compound, a flame retardant additive containing a phosphorus-containing compound, and a hydrolysis suppressing agent suppressing the hydrolysis of the at least one biodegradable organic high molecular compound. An aliphatic polyester resin is polylactic acid, polycaprolactone, polyhydroxy lactic acid, polyhydroxy valeric acid, polyethylene succinate, polybutylene succinate, polybutylene adipate, polymalic acid, polyesters synthesized by fermentation, or a copolymer containing at least one of them. A polysaccharide is cellulose, starch, chitin, chitosan, dextrane, a derivative of at least one of them, or a copolymer containing at least one of them.
... |
| Pharmaceutical composition with healing activity comprising at least one soluble dextran derivative and at least one platelet-derived growth factor | 20070254828 | 20071101 |
| Pharmaceutical composition with healing activity comprising at least one soluble dextran derivative and at least one platelet-derived growth factor. The present invention relates to a pharmaceutical composition with healing activity comprising at least one soluble dextran derivative and at least one platelet-derived growth factor, and also to the use thereof for the preparation of a medicament with healing action, in particular for use in the treatment of ulcers.
... |
| Dry hemostatic compositions and methods for their preparation | 20070248685 | 20071025 |
| Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.
... |
| Colonic drug delivery formulation | 20070243253 | 20071018 |
| A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon
... |
| Polyol-modified silanes as precursors for silica | 20070207484 | 20070906 |
| The invention relates to the preparation of monolithic silica under mild conditions from alkoxysilanes derived from sugars, sugar acids, sugar alcohols and polysaccharides including glycerol, sorbitol, mannose and dextran. Unlike the commonly used silica starting material TEOS (Si(OEt)4), the sol-gel hydrolysis and cure of the sugar derivatives are not very sensitive to pH as similar rates of gelation were observed over a pH range of about 5.5-11. The morphology of the resulting silicas could be varied using specific additives, including multivalent ions and hydrophilic polymers.
... |
| Protein with activity of hydrolyzing dextran, starch, mutan, inulin and levan, gene encoding the same, cell expressing the same, and production method thereof | 20070140989 | 20070621 |
| Disclosed is an enzyme, having the amino acid sequence of SEQ. ID. No. 1 with the activity of hydrolyzing dextran, starch, mutan, inulin and levan, a gene encoding the enzyme, and a transformed cell expressing the gene. Also disclosed is a method of producing an enzyme capable of degrading dextran, starch, mutan, inulin and levan, which comprises culturing the cell, expressing the enzyme in the cell and purifying the enzyme. A composition comprising the enzyme is provided for removing dextran or polysaccharide contaminants during sugar production. With such degradation activity, the enzyme not only finds various applications in the dental care industry, including anti-plaque compositions and mouthwashes, but is also useful in removing dextran or polysaccharide contaminants during sugar production.
... |
| Recombinant production of antimicrobial peptides | 20070104764 | 20070510 |
| The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves... |
| Ferrofluids stable in neutral media and modified ferrofluids modifies obtained by modification of the surface of the particles of said ferrofluids | 20070090323 | 20070426 |
| The invention relates to aqueous dispersions, comprising particles based on a magnetic iron oxide with dimensions of ≦20 nm, the surface of which is modified by the grafting of aminated groups R with a covalent bonding to the surface of said particles, wherein the isoelectronic point of particles with such a modified surface is ≧10. The invention further relates to a method for production of said aqueous suspensions and a method for modification of the surface of the particles present in said dispersions, in particular, by the immobilisation of polysaccharides such as dextrans, particularly for the formulation of magnetic compositions which may be administered in vivo and in particular for the formulation of injectable compositions of contrast agents for MRI.
... |
| Protein with activity of hydrolyzing amylopectin, starch, glycogen and amylose, gene encoding the same, cell expressing the same, and production method thereof | 20070077212 | 20070405 |
| Disclosed are an enzyme, having the amino acid sequence of SEQ. ID. No. 1 with the activity of hydrolyzing amylopectin, starch, glycogen and amylose, a gene encoding the enzyme, and a transformed cell expressing the gene. Also disclosed is a method of producing an enzyme capable of degrading amylopectin, starch, glycogen and amylose, which comprises culturing the cell, expressing the enzyme in the cell and purifying the enzyme. A composition comprising the enzyme is provided for removing dextran or polysaccharide contaminants during sugar production.
... |
| Gel composition for cellular adhesion inhibition | 20070031498 | 20070208 |
| The invention includes compositions for inhibiting cellular adhesion, methods of preparation of such compositions, and methods for preventing cell adhesion at a surgical site comprising application of such compositions. The compositions generally comprise a cellular adhesion inhibitory agent, such as dextran sulfate, and a crosslinked hydrogel matrix, preferentially physically entrapping the adhesion inhibitory agent. The hydrogel matrix can include a first gel component, such as an electrophilically functionalized polyethylene glycol polymer, and at least one additional gel component, preferably nucleophilically functionalized, and preferentially selected from the group consisting of polyethylene glycol polymers, polypeptides, and polysaccharides. The compositions are useful for delivering the cellular adhesion inhibitory agent to a site in need of adhesion inhibition and providing either immediate or metered delivery of the inhibitory agent.
... |
| Polysaccharide pseudo-sponge | 20070009579 | 20070111 |
| wherein Si represents an area of the test specimen before the immersion, and S2 is an area of the test specimen after the immersion, in which the area is calculated from the length and width of the test specimen; and (II) an absorbance of not more than 0.15 at a wavelength of 620 nm as measured with respect to an aqueous solution containing 0.67% by weight of a polysaccharide which is prepared by immersing a test specimen having a thickness of 1 mm, a length of 20 mm and a width of 10 mm, and a solvent content of 96% by weight, in an aqueous solution containing 0.5 g/mL of blue dextran having a weight-average molecular weight of 2,000,000, and then subjecting the test specimen to... |
| Tissue enhancement implant and method | 20070003503 | 20070104 |
| A composition adapted for human tissue enhancement includes crystallized dextran microparticles.
... |
| Photocrosslinked hydrogel blend surface coatings | 20060292701 | 20061228 |
| Hydrogel polymer blends including precursors and crosslinked forms of the compositions. The blends provide an improved approach to achieve high quality, uniform coatings with better commercial viability than other approaches including copolymerization. Applications include mass spectral analysis of biomolecular analytes such as proteins. Dextran and acrylamide systems are preferred. Benzophenone groups can be used as photocrosslinking groups. Photoinitiators are not needed. Functionalities which can selectively bind to biomolecular analytes are included.
... |
| Compositions for use as a signal generation component and methods of using same | 20060270063 | 20061130 |
| wherein R is one or more substituents, each substituent comprising an electron donating group; n=2-10; x=1-2; and y=2-4.
... |
| Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals | 20060264357 | 20061123 |
| The present invention provides a method of treating a human subject to prevent leakage of serum proteins from capillary endothelial junctions during a period of increased capillary permeability and at the same time preventing the harmful effects of free radicals on capillaries and surrounding tissues. The method comprises administering to a subject an effective amount of a composition comprising at least one polysaccharide selected from the group of HES, glycogen and dextran of varying molecular sizes and at least one active agent selected from the group consisting of dehydroascorbic acid, von Willebrand Factor, hemoglobin, polysaccharide-conjugated hemoglobin, Cerovive, edaravone, dimethylthiourea, citicoline, poly(ADP-ribose) polymerase inhibitor, oxidant detoxification catalyst, adenosine 2a (A2a) receptor agonist, adenosine 1 (A1) receptor agonist, adenosine, inosine, xanthin oxidase inhibitor, polyethylene-glycol-modified albumin, adenosine triphosphate, histamine,... |
| Photocrosslinked hydrogel blend surface coatings | 20060252159 | 20061109 |
| Hydrogel polymer blends including precursors and crosslinked forms of the compositions. The blends provide an improved approach to achieve high quality, uniform coatings with better commercial viability than other approaches including copolymerization. Applications include mass spectral analysis of biomolecular analytes such as proteins. Dextran and acrylamide systems are preferred. Benzophenone groups can be used as photocrosslinking groups. Photoinitiators are not needed. Functionalities which can selectively bind to biomolecular analytes are included.
... |
| Metal or metal oxide porous material prepared by use of dextran or related soluble carbohydrate polymer | 20060252640 | 20061109 |
| The present invention provides a new metal or metal oxide porous material and a preparation method thereof, and more particularly concerns a new sponge-shaped noble metal, especially a silver porous material that is useful as a catalyst for an organic synthetic reaction such as an epoxidation reaction and partial oxidation reaction, and a functional material for electronic devices, heat dissipation and bacterial filtration and a preparation method thereof, as well as such a new silver catalyst.
... |
| Long-term shelf preservation of cells and multicellular specimens by vitrification | 20060240399 | 20061026 |
| The method of preservation by vitrification, described in the present application, provides for storage of samples at higher temperatures than in conventional methods and can be applied to cells, multicellular tissues, organs and organisms. The method of the present invention includes preparing a solution of vitrification non-permeating co-solutes (amino acids, betaines, carbohydrates, or other non-permeating co-solutes that effectively decrease the chemical potential of permeating cryoprotectants in aqueous solutions), a permeating cryoprotectant and a non-permeating cryoprotectant (polyvinylpyrrolidone, polyethylene glycol, dextran, hydroxy ethyl starch, Ficoll, etc.), contacting a sample with the vitrification solution and storing the sample at a storage temperature. The method also includes the step of rehydrating the preserved sample in a rehydration solution prepared in the manner of the vitrification storage solution. The present invention... |
| Nucleic acid molecules coding for a dextran-saccharase catalysing the synthesis of dextran with alpha 1,2 osidic sidechains | 20060210510 | 20060921 |
| The invention relates to an isolated polypeptide with an glycosyl transferase enzymatic activity for producing dextrans with α(1→2) sidechains, comprising at least one region for bonding to glucan and a catalytically active region situated beyond the region bonding to glucan. The invention further relates to polynucleotides coding for said enzymes and vectors containing the same.
... |
| Cartilage repair mixture containing allograft chondrocytes | 20060210643 | 20060921 |
| The invention is directed toward a sterile cartilage defect implant material comprising milled lyophilized allograft cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or mixed polymers with allograft chondrocytes added in an amount ranging from 2.5×105 to 2.5×107.
... |
| Materials and methods for preventing and treating microbe-mediated epithelial disorders | 20060198817 | 20060907 |
| The present invention provides pharmaceutical compositions in the form of relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such ad dextran and/or essential pathogen nutrients such as L-glutantine. Also provided are methods for preventing or treating gut-derived sepsis attributable to intestinal pathogens such as Pseudomonas aeruginosa by administering high molecular weight polyethylene glycol as well as methods for monitoring the administration of high molecular weight polyethylene glycol, such as in methods of preventing, ameliorating or treating microbe-induced epithelial disorders, as exemplified by gut-derived sepsis. Frequently, gut-derived sepsis arises as a complication in mammals recovering from surgical intervention or suffering from a disease or disorder, providing indications of suitable animals to receive preventative treatment. Finally, the invention provides a... |
| Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity | 20060199831 | 20060907 |
| Injectable pharmaceutical compositions containing 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimalcate as active ingredient in the form of a lyophilised powder with a carrier selected from lactose and dextran, mixed with sodium chloride.
... |
| Thermostable enzyme compositions | 20060193843 | 20060831 |
| The present invention relates to a composition comprising at least two thermostable enzymes selected from the group consisting of endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, and alpha-galactosidase. The thermostable enzymes have a melting temperature, Tm, of at least 70° C. Preferred compositions comprise a xylanase of glycoside hydrolase family 11, and an endoglucanase which is homologous to a thermostable glycoside hydrolase family 5 endoglucanase derived from Thermoascus aurantiacus. Preferred xylanases are derived from Aspergillus, Bacillus, Humicola, Thermomyces and Trichoderma. The composition is particularly useful for animal feed purposes. Optional additional components are vitamins, minerals, and anti-microbial peptides.
... |
| Method for enriching adherent monocyte populations | 20060183103 | 20060817 |
| The present invention provides methods and apparatus for the rapid and efficient collection and purification of activated monocytes. The methods and apparatus of the present invention provide means for effecting the collection and purification in an aseptic environment. The method involves filtering a blood component mixture through a monocyte-adhering filter; washing the blood component mixture; backflushing the filter with a physiological solution; and backflushing the filter with Dextran-40/serum albumin.
... |
| Compositions for use as a signal generation component and methods of using same | 20060166376 | 20060727 |
| wherein R is one or more substituents, each substituent comprising an electron donating group; n=2−10; x=1−2; and y=2−4.
... |
| Phosphorylated dextrans | 20060154896 | 20060713 |
| Dextrans, which have no immunoreactivity, were revealed to exert immunopotentiating activities on their chemical phosphorylation. Since phosphorylated dextrans not only function as B cell mitogens, but also activate dendritic cells and induce IL-10 and IFN-γ, they can be expected to have effects in preventing infectious diseases and colitis, and in preventing allergic diseases by maintaining the Th1/Th2 balance.
... |
| Serum-free mammalian cell culture medium, and uses thereof | 20060148074 | 20060706 |
| The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.
... |
| Virus preparations and methods | 20060141566 | 20060629 |
| Methods are disclosed for the preparation of herpesvirus, such as herpes simplex virus type 2 for vaccine use. Such viruses can be grown on serum free or serum containing media and can be prepared from the virus containing culture supernatant or virus containing cells. The virus is prepared for subsequent pharmaceutical formulation by methods which may include treatment with solid phase affinity reagents containing sulfate- or sulfonate-comprising binding groups. Such sulfated polysaccharide groups as heparin or dextran sulfate may be used, and eluted with salt solutions. The process can be combined with other culture, harvesting and formulation steps.
... |
| Purification of immunoglobulins | 20060134805 | 20060622 |
| The present invention relates to a separation matrix comprised of porous particles to which antibody-binding protein ligands have been immobilised, wherein the ligand density is in the range of 5.0-10 mg/ml; the gel phase distribution coefficient of the particles expressed as Kav for a dextran of size 110 kDa is above 0.65 and the median particle diameter is between 65-84 μm. The carbohydrate material is preferably highly cross-linked agarose.
... |
| Composition for promoting the proliferation of lactobacillus casei subsp. casei | 20060127378 | 20060615 |
| The present invention relates to a composition for promoting bacterial proliferation for selectively proliferating Lactobacillus casei subsp. casei, which includes a dextran. According to the present invention, a variety of biological activities originated from L. casei subsp. casei can be sustained in a living body by selectively growing-proliferating and colonizing L. casei subsp. casei in the intestine of a human being, animal, or the like or by selectively growing-proliferating L. casei subsp. casei in the intestine, without supplying L. casei subsp. casei at all times.
... |
| Compositions based on polysaccharides and protein c and methods of using the same for preventing and treating sepsis and other conditions | 20060127387 | 20060615 |
| The present invention provides pharmaceutical compositions useful for the prevention and treatment of sepsis and other conditions such as stroke, reperfusion injury and heart attacks, containing 1) at least one macromolecular polysaccharide selected from the group consisting of hydroxyethyl starch, dextran, glycogen and mixtures thereof and 2) activated protein C. The compositions can further comprise at least one member selected from the group consisting of at least one antioxidant and/or at least one anti-infective. The present invention further provides methods of treating human subjects prior to or during sepsis and other conditions such as stroke, reperfusion injury and heart attacks to prevent leakage of macromolecules from capillary endothelial junctions and simultaneously prevent thrombosis and fibrin formation, reduce inflammation and improve microcirculation by intravenously administering to a... |
| Partially biodegradable temperature and ph sensitive hydrogel | 20060128918 | 20060615 |
| Partially biodegradable hydrogel that changes its volume and shape in response to change in pH and/or temperature is prepared by UV irradiation of composition comprising dextran-maleic acid monoester and N-isopropylacrylamide.
... |
| Cohesive coprecipitates of sulfated polysaccharide and fibrillar protein and use thereof | 20060110426 | 20060525 |
| The present invention concerns cohesive biopolymer gels comprising coprecipitates of sulfated polysaccharides and fibrillar proteins, exemplified by coprecipitates of dextran sulfate and gelatin, useful for clinical applications including as implants for tissue engineering as well as in biotechnology. The cohesive biopolymer gels according to the present invention may be used clinically either per se or as a scaffold for a cell-bearing implant, as a depot for sustained release of bioactive agents, or for research and biotechnology.
... |
| Use of dextran sulfate | 20060111319 | 20060525 |
| The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible.
... |
| Ascorbic acid stability | 20060093676 | 20060504 |
| Stable ascorbic acid-dextran conjugates, useful as active constituents in food, pharmaceutical as well as cosmeceutical applications, are described.
... |
| Injectable hydrogel microspheres from aqueous two-phase system | 20060073281 | 20060406 |
| Injectable hydrogel microspheres are prepared by forming an emulsion where hydrogel precursors are in a disperse aqueous phase and polymerizing the hydrogel precursors. In a preferred case, the hydrogel precursors are poly(ethylene glycol) diacrylate and N-isopropylacrylamide and the continuous phase of the emulsion is an aqueous solution of dextran and a dextran solubility reducer. The microspheres will load protein, e.g., cytokines, from aqueous solution.
... |
